GSK external R&D
GlaxoSmithKline places additional emphasis on external partnerships through the creation of Centre of Excellence for External Drug Discovery. The center, headed by Senior VP Maxine Gowen, will manage partnerships formerly overseen by GSK's Alternative Discovery Initiative as well as outsource development of targets and early-stage compounds. Center's structure will be similar to that of GSK's R&D Centres of Excellence for Drug Discovery. Gowen previously served as president of GSK's venture capitalist business SR One; she will be succeeded by Adrian Rawcliffe...
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.